TEVA PHARMACEUTICAL-SP ADR (TEVA) Forecast, Price Target & Analyst Ratings
NYSE:TEVA • US8816242098
31.05 USD
-0.7 (-2.2%)
At close: Mar 6, 2026
30.65 USD
-0.4 (-1.29%)
Pre-Market: 3/9/2026, 5:51:42 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TEVA PHARMACEUTICAL-SP ADR (TEVA).
Forecast Snapshot
Consensus Price Target
$0.11
-99.64% Downside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.52
Revenue Estimate3.876B
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.11
Upside
-99.64%
From current price of $31.05 to mean target of $0.11, Based on 7 analyst forecasts
Low
$0.11
Median
$0.11
High
$0.11
Price Target Revisions
1 Month
-1.91%
3 Months
65.29%
Price Target Summary
7 analysts have analysed TEVA and the average price target is 0.11 USD. This implies a price decrease of -99.64% is expected in the next year compared to the current price of 31.05.
The average price target has been revised upward by 65.29% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
TEVA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TEVA.
In the previous month the buy percentage consensus was at a similar level.
TEVA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-02-18 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-01-30 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-29 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2026-01-29 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-06 | Jefferies | Maintains | Buy -> Buy |
| 2025-12-22 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-19 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-16 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-08 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-05 | ScotiaBank | Initiate | Sector Outperform |
| 2025-11-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-24 | UBS | Maintains | Buy -> Buy |
| 2025-06-26 | UBS | Maintains | Buy -> Buy |
| 2025-06-06 | Goldman Sachs | Initiate | Buy |
| 2025-05-28 | Truist Securities | Initiate | Buy |
| 2025-05-12 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-05-08 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-06 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-30 | UBS | Maintains | Buy -> Buy |
| 2025-01-30 | Barclays | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.52
Revenue Estimate3.876B
Revenue Q2Q-0.39%
EPS Q2Q-1.47%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
-0.64%
Revenue (3 Months)
-4.37%
EPS (1 Month)
-0.34%
EPS (3 Months)
-8.04%
Next Earnings Summary
TEVA is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is 0.52 USD and the consensus revenue estimate is 3.88B USD.
The next earnings revenue estimate has been revised downward by 4.37% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 15.846B 6.17% | 16.544B 4.40% | 17.258B 4.32% | 17.105B -0.89% | 17.535B 2.51% | 18.227B 3.95% | |
| EBITDA YoY % growth | 4.693B 4.45% | 4.647B -0.98% | 5.14B 10.61% | 5.166B 0.51% | 5.543B 7.30% | 6.161B 11.15% | |
| EBIT YoY % growth | 3.54B 11.15% | 3.588B 1.36% | 4.138B 15.33% | 4.536B 9.62% | 4.919B 8.44% | 5.627B 14.39% | |
| Operating Margin | 22.34% | 21.69% | 23.98% | 26.52% | 28.05% | 30.87% | |
| EPS YoY % growth | 2.61 1.19% | 2.54 -2.73% | 2.98 17.27% | 2.81 -5.45% | 3.16 12.19% | 3.54 12.29% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.52 -1.47% | 0.67 -0.01% | 0.77 -3.23% | 0.78 -20.31% |
| Revenue Q2Q % growth | 3.876B -0.39% | 4.217B 0.98% | 4.505B 0.56% | 4.46B -5.33% |
| EBITDA Q2Q % growth | 1.033B 0.39% | 1.292B -10.40% | N/A | N/A |
| EBIT Q2Q % growth | 979.91M 24.83% | 1.132B 19.41% | 1.258B 12.32% | 1.276B -2.22% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
6.00%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1.80%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
11.69%
EBIT Next 5 Year
N/A
TEVA PHARMACEUTICAL-SP ADR / TEVA Forecast FAQ
What is the price target for TEVA stock?
7 analysts have analysed TEVA and the average price target is 0.11 USD. This implies a price decrease of -99.64% is expected in the next year compared to the current price of 31.05.
When does TEVA PHARMACEUTICAL-SP ADR (TEVA) report earnings?
TEVA PHARMACEUTICAL-SP ADR (TEVA) will report earnings on 2026-05-05.
Can you provide the consensus estimates for TEVA PHARMACEUTICAL-SP ADR next earnings?
The consensus EPS estimate for the next earnings of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 0.52 USD and the consensus revenue estimate is 3.88B USD.
What is the expected long term growth rate for TEVA stock?
The expected long term growth rate for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 1.8%.